• Aardvark Therapeutics published its HERO and OLE data update on ARD-101 for Prader-Willi syndrome.
• The FDA lifted the clinical hold on the program; HERO enrolled 67 participants before dosing stopped February 27, 2026.
• HERO showed modest hyperphagia score reductions versus placebo; early termination left results exploratory.
• Former placebo participants showed roughly six-point additional improvement on ARD-101 in the extension; symptoms rebounded following treatment withdrawal.
• One Grade 4 cardiac event occurred at 800 mg twice daily in a participant taking pitolisant; HERO recorded no additional cardiac events.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aardvark Therapeutics Inc. published the original content used to generate this news brief on October 23, 2026, and is solely responsible for the information contained therein.